- “La Caixa” and Inveready invest in Minoryx2013-04-02Minoryx develops new treatments for rare diseases, particularly y for metabolic diseases of genetic origin, which mainly affect children. Through its platform, SEE-Tx, Minoryx combiness proprietary computational technology with biological screenings, in order to identify a new generation of drug gs known as pharmacological chaperones. view pdf